Loading company
AgomAb Therapeutics NV
AGMB · Nasdaq · Healthcare · Biotechnology
$10.51-0.7%Sep 25 close
- 1M
- -20.2%
- 6M
- -3.1%
AGMB · Nasdaq · Healthcare · Biotechnology
$10.51-0.7%Sep 25 close
Three ratings, each a percentile against the 585 companies we cover in Biotechnology. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.
Not enough data to rank
The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.
Middle of its industry
Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 2 of 5 measures.
5 checks not reported
What management does with the money — scored on whatever the filings answer, never as a share of the total.
A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.
Built from AgomAb Therapeutics NV’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This company files in EUR. Figures are converted to US dollars at $1.00 = 0.878890 EUR, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Is the business getting bigger, and does it generate real cash?
Only 2 of the 5 checks below could be answered from this company’s filings, which is too few to put it on the scale. The filings do not go back far enough for the year-on-year comparisons these checks need. Whatever did resolve is still shown — it is just not enough for a letter.
There is no grade history to chart for AgomAb Therapeutics NV yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.